Dr. Patrick Michael Navolanic, MD, PhD

Dr. Navolanic practices at Connecticut Radiation Oncology in Hartford, Connecticut.

Dr. Navolanic's NPI, 1093028110, was assigned on July 18, 2010. Dr. Navolanic graduated from Saint Louis University School of Medicine in 2010. Dr. Navolanic holds New York license 291571.

Dr. Navolanic's primary practice is Connecticut Radiation Oncology, at 94 Woodland St, Hartford, CT 06105 in Capitol County. The practice phone is (860) 714-4568.

Dr. Navolanic's primary practice is Connecticut Radiation Oncology in Hartford, Connecticut. Dr. Navolanic is also affiliated with Saint Francis Hospital. The medical group on file is Connecticut Radiation Oncology, PC. Dmand AI also links Dr. Navolanic to 1 more hospital, 3 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Navolanic practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Navolanic's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Navolanic is licensed in New York.

CMS data shows 1,565 Medicare services from Dr. Navolanic across 14 procedure codes in 2024, for 146 Medicare patients. Medicare paid $112,106 for them. Every service was in an office.

CMS counts 146 Medicare patients who saw Dr. Navolanic in 2024. The largest group is 75 to 84, with 71 patients. 75% of them have cancer, and 75% have high blood pressure. 13% are also on Medicaid. Their average risk score is 1.62, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Navolanic's median patient age at 73, with 48% women.

In 2024, Dr. Navolanic wrote 102 Medicare Part D claims for 45 patients. 87% of them were for generic drugs. CMS names the drug for 43 of them, across 2 drugs with 11 or more claims each, at $458 in total drug cost. In 2023, CMS named 25 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Navolanic for performance year 2024, reported as part of a group. Dr. Navolanic accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Navolanic as offering telehealth.

Dmand AI links 2 papers to Dr. Navolanic, published from 2011 to 2016.

CMS Open Payments shows 9 general payments to Dr. Navolanic from 7 drug and device companies from 2018 to 2024. Food and beverage make up the largest share, 100% of the total. Progenics Pharmaceuticals, Inc. paid the most, $228.

Dr. Navolanic graduated from Saint Louis University School of Medicine in 2010.